Lotus Pharmaceutical Co., Ltd.

1795

TW0001795003

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
284 ^TWD	-1.56%		-1.90%	+4.41%

06-06	Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	CI
05-11	Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Lotus Pharmaceutical Co., Ltd. Announces Change of the Representative of Institutional Director

January 27, 2022 at 04:51 pm

Lotus Pharmaceutical Co., Ltd. appointed Mr. Arni Hardarson as Representative of Institutional Director in place of Joel Morales, effective 1 January 2022.

Latest news about Lotus Pharmaceutical Co., Ltd.

Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	06-05	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-11	CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	03-26	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	01-31	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01-14	CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.	24/09/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes	04/09/23	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15/08/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	31/07/23	CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	11/07/23	MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson	10/07/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members	10/07/23	CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023	16/06/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Board Changes	15/06/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Tenure Expiration of the Remuneration Committee Members	15/06/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Audit Committee Members	15/06/23	CI
Lotus Pharmaceutical Co., Ltd. Announces Change of Directors	15/06/23	CI
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	05/06/23	CI
Lotus Pharmaceutical Co., Ltd. Approves to Enter, Jointly with Alvogen US, into an Exclusive Agreement with NeuroRx Inc. to Develop, Manufacture and Commercialize NRX-101	03/06/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI

Chart Lotus Pharmaceutical Co., Ltd.

Duration

Period

More charts

Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lotus Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

284 TWD

Average target price

393.2 TWD

Spread / Average Target

+38.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LOTUS PHARMACEUTICAL CO., LTD.	+4.41%	2.32B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals